(Q34394082)

1 August 2017

1 reference

title

New therapeutic concepts in prostate cancer (English)

1 reference

1 August 2017

1 reference

Hamdy FC

1

1 reference

1 August 2017

Thomas BG

series ordinal

2

1 reference

1 August 2017

publication date

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

88 Suppl 2

1 reference

1 August 2017

page(s)

43-8; discussion 49-50

1 reference

Population-based study of long-term survival in patients with clinically localised prostate cancer.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

The proto-oncogene Bcl-2 and its role in regulating apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Target sites for manipulating apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Bone: formation by autoinduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-410X.2001.00118.X

10.1046/J.1464-410X.2001.00118.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference